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rediffmail.com (B. Bhattacharya)IntroductionLeprosy reactions are immunological complications that occur
before, during or after the completion of multidrug therapy.
Two major types of complications may occur, type 1 and type 2
[1–3]. These distinct conditions occur separately and arise at
different times in some patients. The type 1 complication is a
delayed hypersensitivity reaction; the dermatopathologic fea-
tures of acute type 1 reactions are oedema, increased number
of lymphocytes in the dermis and loss of normal granuloma
organization. These reactions appear to be mediated via Th1
lymphocytes, and cells from reaction lesions express the pro-
inﬂammatory cytokines interferon (IFN) gamma, interleukin
12 and the free radical producer inducible nitric oxide synthase.
The type 2 reaction, erythema nodosum leprosum (ENL), isNew Microbes and New Infections © 2015 The Authors. Published by El
This is an open access artiserious and difﬁcult to manage, particularly the immunologic
complications of borderline lepromatous and lepromatous
leprosy. High levels of circulating tumour necrosis factor alpha
(TNF-α) have been demonstrated in the plasma of some in-
dividuals with type 2 reactions. In vitro peripheral blood
mononuclear cells (PBMCs) from individuals with ENL secrete
increased amounts of TNF-α after stimulation [4–6].
Vitamin D2 (ergocalciferol) and vitamin D3 (cholecalciferol)
are the two major forms of vitamin D. Vitamin D3, the active
form of vitamin D, not only regulates calcium and bone meta-
bolism but also plays an immunomodulatory role mediated
through binding of its receptor (VDR) in monocytes, macro-
phages and activated lymphocytes.
Previous studies have demonstrated a deﬁciency of the
secosteroid vitamin D in mycobacterial diseases. This vitamin D
deﬁciency has been found to have a strong negative correlation
with the rise in pro-inﬂammatory cytokines such as TNF-α. As
observed previously, a signiﬁcant increase in TNF-α has been
found the skin lesions of patients with leprosy having type 2
reactions, where it acts as an inﬂammation modulator. More-
over, high levels of TNF-α have been implicated in the direct
damage of myelin sheath of the neurons, stimulation of bone
reabsorption and inhibition of bone collagen synthesis. TheseNew Microbe and New Infect 2015; 6: 35–39
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such as nerve impairment, disability and deformity that are
often observed in leprosy patients. Although no evidence for a
deﬁciency in serum vitamin D in leprosy cases has yet been
reported, the indirect evidence of having bone deformities due
to low calcium absorption suggests that vitamin D deﬁciency
may play a role in leprosy [7]. However, it has been well
established that host cell–mediated immunity decides the
progression and severity of leprosy diseases, although the role
of secosteroid cannot be neglected. Because vitamin D3 exerts
its immunomodulatory effects through binding to VDR, its cell
expression is a crucial determinant for the pathogenesis of viral
or bacterial diseases. A few studies have suggested that certain
mutations of the VDR gene might be associated with leprosy
disease progression [8,9], but no study has yet reported that an
alteration in VDR expression can change the complexity of a
leprosy reaction. In the present study, we conducted a sys-
tematic study on patients with leprosy reaction to assess VDR
expression in PBMCs.FIG. 1. (A) Skin lesions in typical type 1 and type 2 reactions among leprosy
vitamin D3 (ng/ml), pro- and anti-inﬂammatory cytokines (pg/ml) among lepr
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Patients with leprosy from Kolkata, India, were selected ac-
cording to World Health Organization guidelines. Reaction
status was diagnosed as redness, swelling with tenderness of
existing lesion or ulceration (Fig. 1(A)). The corresponding
nerves also exhibited swelling, pain and tenderness, often
accompanied by loss of function, which was taken to be a type 1
reaction, and recurrent crops of red, pink or dusky brown,
painful, small dome-shaped papules or large nodules with ill-
deﬁned margins that were tender upon touch, along with ten-
der and enlarged nerves (Fig. 1(A)). Type 2 reactions are a
systematic disorder affecting many organ systems. The lesions
may be superﬁcial or deep, causing panniculitis (Fig. 1(A)). ENL
may present as a systemic illness; high fever, systemic upset and
prostration were taken to indicate type 2 reactions. Equal
numbers of subjects having no symptoms of infection, having nopatients from Kolkata, India. (B) Tabular presentation of serum levels
osy reaction patients and healthy controls.
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and having normal levels of serum 25-hydroxy vitamin D
(25(OH)D; 30–40 ng/mL) were assigned as healthy controls.
Bacillary index
Bacillary index (BI) was determined by Ziehl-Neelsen staining.
In brief, slit skin was stained with carbol fuchsin and counter-
stained with methylene blue. Stained slides were observed
under a 100× oil immersion lens, and BI was clustered ac-
cording to World Health Organization guidelines.
TNF-α estimation
Blood samples were collected from each of the patients having
type 1 and type 2 reactions before treatment with steroids,
which are commonly used to suppress inﬂammation. The
serum was separated and stored in aliquots at −65°C to −70°C.
The assay was performed as per the protocol supplied using the
commercially available sandwich micro-ELISA assay (Ray
Biotech, UK).
25(OH)D estimation
Blood collected for serum analysis was allowed to clot for 30
minutes at room temperature before centrifugation at
3000 rpm for 10 minutes. Serum 25(OH)D concentrations
were determined from serum samples via immunochemilumi-
nometric assay by a commercial laboratory. The normal level
was taken to be 30 to 40 ng/mL.
RNA isolation and real-time quantitation for VDR
expression
PBMCs from leprosy reaction patients were isolated by Ficoll-
Hypaque (Histopaque; Sigma, USA) gradient. Total RNAs were
isolated by Trizol reagent (Ambion, USA) following the manu-
facturer’s protocol. Total RNA (500 ng) was used to prepare
cDNA using a reverse transcription kit (Fermentus, UK) as per
the manufacturer’s instructions. Quantitative real-time PCR for
VDR expression was performed using a VDR-speciﬁc primer
pair and SYBR Green dye (Power SYBR Green; Applied Bio-
systems, USA). GAPDH (glyceraldehyde phosphate dehydro-
genase) mRNAs were also quantitated and used as internal
control for real-time PCR. Cycle thresold (Ct) values for VDR
were determined and VDR expressions normalized to GAPDH
compared. All experiments were performed in triplicate;
average values are presented.
Western blot analysis
VDR proteins from healthy and leprosy reaction patients were
extracted using radioimmunoprecipitation assay lysis buffer in
presence of protease inhibitor cocktail. Proteins were sepa-
rated in 10% polyacrylamide gels and transferred toNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artinitrocellulose membrane. Proteins were then blotted using
rabbit anti-VDR antibody (Santa Cruz Biotechnology, USA).
Rabbit anti-GAPDH antibody was used as internal control.
Horseradish peroxidase–conjugated goat anti-rabbit secondary
antibody was used for detection in the presence luminol sub-
strate (Pierce, USA).ResultsPro- and anti-inﬂammatory cytokine and vitamin D3
proﬁle
Leprosy infection was determined in tissue samples of reaction
patients by PCR using primers speciﬁc for Mycobacterium lep-
rae, as described elsewhere [10] (data not shown). The BI was
also measured from tissue samples of leprosy reaction patients
by Ziehl-Neelsen staining, as described in Materials and
Methods. BI was found to range from 1+ to 6+. Higher BIs
were observed among individuals with type 2 reactions and
ENL or neuritis.
Blood samples were collected from 15 individuals with
leprosy but no reaction and 15 individuals with leprosy reaction
and compared to healthy controls (n = 15). Serum samples
were examined for vitamin D3 levels and for pro- and anti-
inﬂammatory cytokines by CLIA and ELISA to better under-
stand infection status. The levels of vitamin D3 in healthy
controls were 33 ± 3.76 ng/ml, whereas it was 19 ± 3.6 ng/ml in
reaction patients (Fig. 1(B)). Increased TNF-α, interleukin 10
and IFN-α levels were observed among reaction individuals,
whereas decreased levels of IFN-γ and IFN-β were determined
compared to healthy individuals (Fig. 1(B)). These results are
typical of leprosy disease progression.
Quantitation and analysis of VDR among leprosy
reaction individuals
To determine whether vitamin D receptor protein or VDR play
any role in immunity and control of leprosy disease progres-
sion, we measured VDR mRNA expression in PBMCs of
infected individuals by quantitative real-time PCR and compared
it to that of healthy controls (Fig. 2(A)). Comparison of VDR
expression was made by determining the Ct values and was
then normalized with GAPDH. Analysis revealed that six
samples had signiﬁcantly lower amounts of VDR mRNAs
compared to healthy controls. VDR mRNAs in two of the
samples were only 4% and 5%, respectively, compared to that
of the control samples, whereas the other four had 10–20%
VDR expression (Fig. 2(A)). Interestingly, all the individuals with
low VDR expression manifested type 2 reactions, with neuritis
and/or ENL. Four individuals had low vitamin D levels, and two
had normal serum levels of vitamin D.lf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 35–39




FIG. 2. (A) Real-time quantitative PCR for determining vitamin D receptor (VDR) mRNA expression levels among leprosy reaction patients and
healthy controls. SYBR Green–based quantitative PCR was done using primers speciﬁc for VDR. The GAPDH (glyceraldehyde phosphate dehydro-
genase) gene was quantiﬁed as an internal control. Experiments were performed in triplicate, and average values are presented. (B) VDR expression
levels in leprosy reaction patients and healthy controls, as determined by Western blot analysis. Peripheral blood mononuclear cells (PBMCs) were
isolated and total proteins were analyzed on a 10% PAGE gel. VDR and GAPDH proteins were detected with rabbit anti-VDR and rabbit anti-GAPDH
antibody, respectively. Chemiluminescence was measured, and the ratio of VDR to GAPDH was calculated and graphically presented. (C) Tabular
representation of bacillary index, reaction types and VDR expression levels among patients with leprosy.
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VDR protein levels, we analyzed VDR protein expressions from
individuals with low VDR mRNA and compared it to that of
healthy control and type 1 samples. Our result from a repre-
sentative type 2 sample clearly showed that low VDR mRNA-
expressing samples had low VDR protein compared to con-
trols with normal VDR mRNA levels, whereas control GAPDH
protein levels remained similar (Fig. 2(B)).DiscussionVitamin D3 acts through its receptor, VDR, which, upon binding
to vitamin D3, gets activated and regulates transcription of
different classes of genes, including those involved in immune
reaction. Thus, VDR expression levels in these cell types are
important in controlling disease progression. VDR binds to
VDR response element and regulates gene expression [11].
ChIP-seq analysis showed that upon vitamin D3 stimulation,New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
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coupled with enriched VDR binding [12]. VDR binding sites are
signiﬁcantly enriched near autoimmune diseases and cancer-
associated genes identiﬁed from genome-wide associated
studies. Notable genes with VDR binding included IRF8, asso-
ciated with multiple sclerosis, and PTPN2, associated with
Crohn disease and type 1 diabetes [13]. VDR is suggested to
play an important role in miRNA regulation and thus might be
indirectly involved in the key regulation of other genes. VDR
also regulates the MCM7 gene, which encodes MIR 106b and is
known to regulate the expression of MIR181a and MIR-22
[14,15]. MicroRNA regulation is linked to several diseases, and
their presence is sometimes used as a marker for them.
Previous studies have shown that certain mutations in the
VDR gene are associated with leprosy complexity [8,9]. Here
we have shown that individuals with complex leprosy reactions
have very low VDR expression in association with low vitamin
D3. These individuals had very high BI, and all had ENL. Inter-
estingly, two individuals with normal vitamin D3 levels but withEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 6, 35–39
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2 reaction with neuritis and/or ENL. This suggests not only that
a certain level of vitamin D3–VDR interaction is crucial but also
that the level of VDR expression is the determining factor in
controlling leprosy reaction. We do not yet know how VDR
expression affects the outcome of leprosy reaction. Under-
standing the exact mechanism is of interest and remains to be
elucidated. ChIP-seq analysis of leprosy reaction patients’ genes
may provide detailed information.
This is a signiﬁcant ﬁnding which may explain not only
leprosy but also other diseases linked to vitamin D levels, such
as diabetes. It will be interesting to discover the speciﬁc genes
regulated by VDR expression that may affect disease outcome.
Moreover, VDR therapy may be helpful in treating individuals
with leprosy.
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